Literature DB >> 35459560

ADAR1 and its implications in cancer development and treatment.

Allison R Baker1, Frank J Slack2.   

Abstract

The family of adenosine deaminases acting on RNA (ADARs) regulates global gene expression output by catalyzing adenosine-to-inosine (A-to-I) editing of double-stranded RNA (dsRNA) and through interacting with RNA and other proteins. ADARs play important roles in development and disease, including an increasing connection to cancer progression. ADAR1 has demonstrated a largely pro-oncogenic role in a growing list of cancer types, and its function in cancer has been attributed to diverse mechanisms. Here, we review existing literature on ADAR1 biology and function, its roles in human disease including cancer, and summarize known cancer-associated phenotypes and mechanisms. Lastly, we discuss implications and outstanding questions in the field, including strategies for targeting ADAR1 in cancer.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ADARs; RNA editing; cancer; epitranscriptomics

Mesh:

Substances:

Year:  2022        PMID: 35459560      PMCID: PMC9283316          DOI: 10.1016/j.tig.2022.03.013

Source DB:  PubMed          Journal:  Trends Genet        ISSN: 0168-9525            Impact factor:   11.821


  100 in total

1.  Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis.

Authors:  Phaik Ju Teoh; Omer An; Tae-Hoon Chung; Jing Yuan Chooi; Sabrina H M Toh; Shuangyi Fan; Wilson Wang; Bryan T H Koh; Melissa J Fullwood; Melissa G Ooi; Sanjay de Mel; Cinnie Y Soekojo; Leilei Chen; Siok Bian Ng; Henry Yang; Wee Joo Chng
Journal:  Blood       Date:  2018-07-30       Impact factor: 22.113

2.  Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.

Authors:  Jeffrey J Ishizuka; Robert T Manguso; Collins K Cheruiyot; Kevin Bi; Arpit Panda; Arvin Iracheta-Vellve; Brian C Miller; Peter P Du; Kathleen B Yates; Juan Dubrot; Ilana Buchumenski; Dawn E Comstock; Flavian D Brown; Austin Ayer; Ian C Kohnle; Hans W Pope; Margaret D Zimmer; Debattama R Sen; Sarah K Lane-Reticker; Emily J Robitschek; Gabriel K Griffin; Natalie B Collins; Adrienne H Long; John G Doench; David Kozono; Erez Y Levanon; W Nicholas Haining
Journal:  Nature       Date:  2018-12-17       Impact factor: 49.962

3.  Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons.

Authors:  Takuto Hideyama; Takenari Yamashita; Hitoshi Aizawa; Shoji Tsuji; Akiyoshi Kakita; Hitoshi Takahashi; Shin Kwak
Journal:  Neurobiol Dis       Date:  2011-12-28       Impact factor: 5.996

4.  Increase in ADAR1p110 activates the canonical Wnt signaling pathway associated with aggressive phenotype in triple negative breast cancer cells.

Authors:  Fernanda Morales; Paola Pérez; Julio C Tapia; Lorena Lobos-González; José Manuel Herranz; Francisca Guevara; Pamela Rojas de Santiago; Esteban Palacios; Rodrigo Andaur; Eduardo A Sagredo; Katherine Marcelain; Ricardo Armisén
Journal:  Gene       Date:  2022-02-02       Impact factor: 3.688

5.  ADAR1p150 regulates the biosynthesis and function of miRNA-149* in human melanoma.

Authors:  M M Yujie Ding; Xin Shi; Jiang Ji; Yuhua Su
Journal:  Biochem Biophys Res Commun       Date:  2020-01-17       Impact factor: 3.575

6.  Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma.

Authors:  Yan-Ru Qin; Jun-Jing Qiao; Tim Hon Man Chan; Ying-Hui Zhu; Fang-Fang Li; Haibo Liu; Jing Fei; Yan Li; Xin-Yuan Guan; Leilei Chen
Journal:  Cancer Res       Date:  2013-12-03       Impact factor: 12.701

7.  Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence.

Authors:  Zhong Wu; Jin Zhou; Xiaoyang Zhang; Zhouwei Zhang; Yingtian Xie; Jie Bin Liu; Zandra V Ho; Arpit Panda; Xintao Qiu; Paloma Cejas; Israel Cañadas; Fahire Goknur Akarca; James M McFarland; Ankur K Nagaraja; Louisa B Goss; Nikolas Kesten; Longlong Si; Klothilda Lim; Yanli Liu; Yanxi Zhang; Ji Yeon Baek; Yang Liu; Deepa T Patil; Jonathan P Katz; Josephine Hai; Chunyang Bao; Matthew Stachler; Jun Qi; Jeffrey J Ishizuka; Hiroshi Nakagawa; Anil K Rustgi; Kwok-Kin Wong; Matthew Meyerson; David A Barbie; Myles Brown; Henry Long; Adam J Bass
Journal:  Nat Genet       Date:  2021-05-10       Impact factor: 41.307

8.  p150 ADAR1 isoform involved in maintenance of HeLa cell proliferation.

Authors:  Haifang Wang; Zheng Hou; Yumei Wu; Xue Ma; Xiaoxing Luo
Journal:  BMC Cancer       Date:  2006-12-08       Impact factor: 4.430

9.  Profiling RNA editing in human tissues: towards the inosinome Atlas.

Authors:  Ernesto Picardi; Caterina Manzari; Francesca Mastropasqua; Italia Aiello; Anna Maria D'Erchia; Graziano Pesole
Journal:  Sci Rep       Date:  2015-10-09       Impact factor: 4.379

10.  ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity.

Authors:  Julia Ramírez-Moya; Allison R Baker; Frank J Slack; Pilar Santisteban
Journal:  Oncogene       Date:  2020-03-10       Impact factor: 9.867

View more
  4 in total

Review 1.  RNA modifications: importance in immune cell biology and related diseases.

Authors:  Lian Cui; Rui Ma; Jiangluyi Cai; Chunyuan Guo; Zeyu Chen; Lingling Yao; Yuanyuan Wang; Rui Fan; Xin Wang; Yuling Shi
Journal:  Signal Transduct Target Ther       Date:  2022-09-22

Review 2.  ADAR2 enzymes: efficient site-specific RNA editors with gene therapy aspirations.

Authors:  Khadija Hajji; Jiří Sedmík; Anna Cherian; Damiano Amoruso; Liam P Keegan; Mary A O'Connell
Journal:  RNA       Date:  2022-07-21       Impact factor: 5.636

Review 3.  ADAR1-Mediated RNA Editing and Its Role in Cancer.

Authors:  Jizhe Liu; Fei Wang; Yindan Zhang; Jingfeng Liu; Bixing Zhao
Journal:  Front Cell Dev Biol       Date:  2022-07-11

4.  RNA Editing Enzyme ADAR1 Regulates METTL3 in an Editing Dependent Manner to Promote Breast Cancer Progression via METTL3/ARHGAP5/YTHDF1 Axis.

Authors:  Yi Li; Ning-Xi Wang; Chuan Yin; Shan-Shan Jiang; Jia-Chu Li; Sheng-Yong Yang
Journal:  Int J Mol Sci       Date:  2022-08-25       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.